Do you own Matrixx stock (Nasdaq - MTXX)? I work with a law firm investigating reports of possible securities law violations by Matrixx Initiatives, Inc., the maker of Zicam. In a letter to Matrixx, the FDA concluded certain Zicam products may pose serious risks to consumers. When the letter was released, Matrixx stock plummeted from approximately $19 per share to less than $7 per share. Since December 2007, insiders have sold more than $2.7 million worth of Matrixx shares. Learn more: www.hbsslaw.com/matrixx
- Joined July 22, 2009
- Last Visit July 22, 2009
IN THESE TIMES COMMUNITY MEMBERS
